This presentation by Carol Tamminga, United States, was recorded on 21 January 2025 at the ECNP Roadmap Meeting on Precision Psychiatry in Frankfurt, Germany.
The talk discusses the BSNP study, which aims to develop biomarkers for psychosis, focusing on schizophrenia, schizoaffective disorder, and psychotic bipolar disorder. The study finds that classifying based on biological characteristics is more effective than traditional diagnoses. By measuring various biomarkers, the study identifies distinct biotypes with different EEG activity patterns. Tamminga highlights the potential of clozapine to normalise EEG activity and introduces Conexus 5356, a drug targeting cognition in schizophrenia. She emphasises the importance of biological diagnoses and the potential of biomarkers to advance precision psychiatry and improve patient outcomes.
Views and opinions expressed in these videos are those of the presenters and do not necessarily reflect the official position of ECNP. The content of these videos should not be used in any way as the basis for treatment decisions.
